NCT01954251 - Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older | Biotech Hunter

Enrollment

829

Participants

Timeline

Start Date

October 3, 2013

Primary Completion Date

June 2, 2014

Study Completion Date

March 20, 2015

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster vaccine GSK 1437173A

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

BIOLOGICAL

GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A

2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.

Trial Locations (20)